Who is eligible for clinical trial NCT07764978?

Participants must meet protocol criteria for Newly Diagnosed Multiple Myeloma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07764978 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-10

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT (NCT07764978)

Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.

Who can join: Review the eligibility criteria below.

Location: Research Site — Gilbert, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (124 Sites)

Showing the first 25 of 124 sites.

Research Site — Gilbert, Arizona
Research Site — Phoenix, Arizona
Research Site — Tucson, Arizona
Research Site — Orange, California
Research Site — Santa Monica, California
Research Site — Aurora, Colorado
Research Site — Denver, Colorado
Research Site — New Haven, Connecticut
Research Site — Coral Gables, Florida
Research Site — Tampa, Florida
Research Site — Atlanta, Georgia
Research Site — Chicago, Illinois
Research Site — Iowa City, Iowa
Research Site — Wichita, Kansas
Research Site — Louisville, Kentucky
Research Site — Baton Rouge, Louisiana
Research Site — Baltimore, Maryland
Research Site — Detroit, Michigan
Research Site — St Louis, Missouri
Research Site — East Brunswick, New Jersey
Research Site — Albany, New York
Research Site — New Hyde Park, New York
Research Site — New York, New York
Research Site — New York, New York
Research Site — New York, New York

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Newly Diagnosed Multiple Myeloma

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM — New York, New York
Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma — Boston, Massachusetts

Explore by condition: All Newly Diagnosed Multiple Myeloma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗